DSO Earnout Structure: What to Expect After Your Practice Is Acquired

A $2.6 million offer letter and a $1.82 million wire are the same deal. One of those numbers is marketing. The gap is the earnout, the rollover equity, and the quiet assumption that you'll keep producing like an owner while getting paid like an associate.

Here's the part worth texting to your spouse: the earnout is the only piece of your sale price the buyer gets to grade, and they also write the test.

Our view, and it's the one an informed owner will argue with: when you compare DSO offers, price the earnout at zero. Not discounted, not risk-adjusted, zero. Decide between two deals on cash at close and the quality of the rollover paper, and treat every earnout dollar as a bonus you'd be pleasantly surprised to see. Plenty of smart sellers disagree. They'll tell you the earnout is hittable, that they know their numbers, that they've never had a down year. They're not wrong about their practice. They're wrong about who controls the denominator after closing.

Where the Other 15 to 40 Percent of Your Price Goes

Start with the structure, because almost nobody gets a clean all-cash exit anymore. McLerran & Associates, a sell-side dental M&A firm with roughly 2,000 closed sales behind it, puts the typical DSO deal at 60 to 85 percent cash at close, 10 to 30 percent rollover equity in the DSO's holding company, and a one-to-three-year earnout tied to post-close EBITDA maintenance. Deal Prospectors lands in the same territory: only 60 to 80 percent is cash at closing, with a 15 to 40 percent equity stake, an earnout measured over 12 to 36 months, and a post-sale employment commitment of three to five years as a clinical associate.

Scott Leune's 2026 framework narrows the window: most DSO earnout periods range from 12 to 36 months, with 24 months being most common, and rollover requirements run 10 to 30 percent of deal value. CT Acquisitions, drawing on Skytale Group and Provident Healthcare Partners data, reports that two-year earnouts on associate-doctor production milestones were standard for DSO add-on transactions, with the longer three-plus-year structures showing up on platform deals where the target carries $10 million or more in adjusted EBITDA.

Then the number that should reset your expectations. By McLerran's count, only 50 to 60 percent of earnouts pay out in full. That is not a rounding error. That is a coin flip on the back end of your retirement.

And it's not a niche problem. The ADA Health Policy Institute's September 2025 analysis of roughly 200,000 practicing dentists found that in 2024, more than one in four dentists up to 10 years out of dental school were affiliated with a DSO. The structure described above is now the default career path, not the exotic option.

Which Side of the Table You're Actually On

Before you negotiate an earnout, know which deal you're in. The 10.0x to 15.0x adjusted EBITDA multiples CT Acquisitions reports for 2024 through Q2 2026 belong to platform-tier targets at $10 million-plus in adjusted EBITDA. That is a 40-location group, not a practice.

Look at what's actually changing hands. In the Practice Market Index, our dataset of dental practices currently listed for sale, median collections sit at $1,000,000 with the middle half between $660,250 and $1,500,000 (n=858), and the median practice has 5 operatories (n=855). Collections per operatory run a median of $200,000 (n=733). These are asking-side figures for practices on the market, not a snapshot of every practice in the country. But the shape is clear: the seller meeting a DSO is almost always a single-location add-on.

That matters because add-on sellers get the add-on terms: the two-year production-milestone earnout, the mid-range cash percentage, the employment agreement. You don't get platform economics, and you don't get platform-level negotiating room on the EBITDA definition either. Walking in expecting otherwise is how owners end up signing documents they didn't read closely.

A $2.6M Offer That Wires $1.82M

Work the numbers on a six-operatory general practice collecting $1.4 million with $400,000 of adjusted EBITDA after normalizing owner compensation to what a replacement associate would cost. The DSO offers $2.6 million total.

Cash at close, at 70 percent, is $1,820,000. Rollover equity at 20 percent is $520,000 of paper in the holding company. The remaining 10 percent, $260,000, is an earnout paid in two tranches at months 12 and 24, each one conditioned on the practice holding $400,000 of EBITDA.

Now the thing that happens in nearly every post-close year one: the seller drops from five clinical days to four. Call it an 8 percent hit to collections, which is $112,000. Collections land at $1,288,000. Variable costs track down with it at roughly 35 percent, saving $39,200. EBITDA falls $72,800 to $327,200. That is 18.2 percent below the target.

Most earnouts are cliff-structured, not pro-rated. Miss the number and tranche one, $130,000, pays nothing.

It gets worse if the EBITDA definition doesn't carve out the DSO's own management fee. A 4 percent fee on $1,288,000 is $51,520. Charge that below the line and EBITDA is $275,680, a 31 percent miss on a target you were told was conservative.

Apply the industry-wide payout rate to the whole earnout and you get the honest expected value: $260,000 at 55 percent is $143,000. You are being asked to accept $117,000 of headline price in exchange for nothing contractually guaranteed. We wouldn't call that purchase price. We'd call it a performance bonus with a sales pitch attached.

What Most Owners Get Wrong: Signing a Target Without Owning the Definition

The specific mistake is this. Solo owners in their late fifties, usually represented by a general business attorney rather than a dental M&A specialist, negotiate the size of the earnout and ignore the definition of EBITDA that governs it.

They spend three weeks arguing the holdback down from 15 percent to 10 percent and sign a definitions exhibit they skimmed. That exhibit is where the deal actually lives. It decides whether the management fee sits above or below the line, whether the new PPO fee schedule the DSO negotiates counts as your problem, whether a hygienist you can't replace in a tight labor market is a permitted add-back, and whether a $90,000 CBCT the DSO insists on hits your EBITDA as a lease expense.

The second version of the same mistake: accepting an earnout measured on associate-doctor production when you're the only doctor in the building. CT Acquisitions reports production-milestone earnouts are standard for add-ons. If the DSO hires your associate, sets their compensation, controls their schedule and owns the recruiting process, and you are the one whose $130,000 tranche depends on that associate's numbers, you've guaranteed a result you cannot produce. You can't be an employee and a guarantor at the same time.

The Four Levers They Pull After the Wire Clears

Every one of these is a legitimate business decision for the buyer and a direct hit to your earnout denominator.

• Fee schedules. The DSO's network contracts replace yours. Sometimes that's a raise. Sometimes you inherit a worse schedule on your highest-volume plan because it's better across their other 38 locations.
• The management fee. Typically 4 to 8 percent of collections. Where it sits relative to your EBITDA calculation is worth more than every other term you'll negotiate.
• Staffing and scheduling. Centralized call centers, standardized hygiene intervals, new recall software, and a staffing ratio set at the regional level. Your production per operatory changes and you didn't vote.
• Supply, lab and capital. Preferred vendors can cut your costs. They can also move you to a lab your patients notice, and remakes land in your column.

None of that is bad faith. It's integration. But integration and a maintenance-based earnout are structurally at odds, and the party holding the paper is the one who absorbs the conflict.

The Five Clauses We'd Refuse to Sign Without

We'd walk from a deal missing these before we'd negotiate price.

• Add-backs for buyer-initiated change. Any fee schedule change, management fee, corporate allocation, mandated capital expense or staffing directive originating with the DSO is added back to EBITDA for earnout purposes. In writing, with examples.
• Pro-rated payout, not a cliff. Hit 92 percent of target, collect 92 percent. A cliff hands the buyer a free option on your money.
• Measurement you can audit. Monthly reporting on the earnout calculation, access to the underlying ledger, and a defined dispute process. If you can't see the math monthly, you'll find out you missed in month 13.
• Your own production capped as a variable. If the earnout depends on doctor production, it should be measured against the clinical schedule your employment agreement actually commits you to, not last year's five-day owner pace.
• Twenty-four months, maximum. Leune and Deal Prospectors both point to 24 months as the norm. A 36-month structure on a single-location add-on is the buyer importing platform terms into a non-platform deal. Push back and watch whether they fold.

And on rollover: ask for the holding company's last two years of financials, the debt schedule, and the specific terms of your liquidation preference. Rollover equity sitting behind two layers of preferred stock in a platform carrying heavy acquisition debt is not a second bite at the apple. It's a lottery ticket with a lockup.

Do This Before You Counter

Rebuild your trailing-twelve EBITDA yourself, then rebuild it again assuming you work one fewer clinical day and the DSO charges a 6 percent management fee below the line. If that second number misses the earnout target, the target is wrong and you say so this week, not after diligence. Hire a dental-specific M&A attorney for the definitions exhibit alone, which is a $10,000 expense protecting a $260,000 position. Then rank the offers on your desk by cash at close only, and see whether the ranking changes.

Most owners have never stress-tested their adjusted EBITDA against a four-day schedule and a management fee, which is exactly the number a DSO will model before they call you. Benchmark your own practice value with our free valuation calculator and run your own numbers before someone else runs them for you.

What we're watching into 2027: whether add-on earnout terms stretch past 24 months as platform debt costs stay elevated, and whether that 50 to 60 percent full-payout rate holds or slides. One thing would change our position on pricing earnouts at zero: escrow-funded earnouts with a guaranteed floor tranche. If buyers start putting the money in escrow rather than on a term sheet, we'll start counting it.